Study participants who had taken beta blockers
alone or in combination with another blood pressure medication had significantly less shrinkage in their brains.
As the name implies, beta blockers
can specifically block beta receptors without interfering with lung function.
The harmful effects of beta blockers
in patients with heart failure who do not have contraindications are small.
The tablets cost pounds 22 for a full-strength monthly course, while beta blockers
cost pounds 8.
Recent evidence that two other first-line therapies for CHF-angiotensin converting enzyme inhibitors and digoxin-may be less effective in women makes the beta blocker
issue particularly relevant.
The study also revealed that even long-term use or subtypes of beta blockers
showed no reduction of colorectal cancer risk.
This might encourage people to take beta blockers
,'' Peters said.
Like other beta blockers
, possible factors that may be involved include decreased heart rate and myocardial contractility, and suppression of renin activity.
But our research shows there are no adverse effects and in fact, when used in addition to regular treatments like inhalers, the beta blockers
have a very positive effect," added Lipworth.
The State of Health Care Quality, published by the National Council for Quality Assurance (NCQA), reports that more than 90 percent of heart attack patients are prescribed a beta blocker
within seven days of leaving the hospital.
It is especially important to tell your doctor should you decide to stop using your beta blocker
ZIAC minimizes side effects: "In ZIAC's unique low-dose composition, the beta blocker
and diuretic complement each other and act synergistically to lower blood pressure, while minimizing the side effects patients experience when they take these medications separately," Dr.
Everitt of the Presbyterian Medical Center in Philadelphia offer evidence that may clear the shadow of depression from the beta blocker
Nasdaq:ABIO), a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases, announced today that a comparative analysis of primary endpoint data from four beta blocker
trials was presented at the American College of Cardiology 58th Annual Scientific Session being held March 29-31, 2009.
In addition to research being presented at ARVO, Pharmos announced today the successful completion of Phase I clinical trials on Adaprolol Maleate, a novel eye-active beta blocker
for glaucoma with a favorable side effect profile, including no systemic activity and an absence of cardiovascular and pulmonary side effects normally associated with beta-blockers.